BTT Medical Institute has launched a first-in-human safety trial of the Abreu BTT 700, a noninvasive system that induces controlled hyperthermia through cyclical thermal modulation to evaluate safety and biological effects in amyotrophic lateral sclerosis. The trial represents the first clinical assessment of this technology following over a decade of preclinical work and an FDA clearance issued in 2010.
Key Points
- First-in-human safety trial of brain-guided induced hyperthermia for ALS treatment initiated
- Technology uses cyclical thermal modulation to raise body temperature into controlled fever range
- Trial follows decade-long preclinical development and single-patient case report of ALS reversal
Longevity Analysis
This trial addresses a fundamental principle in neurodegenerative disease: the role of controlled thermal stress in modulating cellular and immune function. Fever-range hyperthermia may engage defense mechanisms and stress response pathways that support neuronal regeneration and protein homeostasis — effects difficult to achieve pharmacologically. The noninvasive, brain-guided approach allows precise modulation of temperature response, potentially reducing the collateral damage associated with systemic fever while preserving adaptive signaling. Success in ALS could establish a platform applicable to broader neurodegenerative conditions where thermal stress response has been implicated in slowing or reversing motor neuron loss.
Original published by Longevity.Technology.